Joseph Todisco Cor Medix Inc. (CRMD) insider trading activity

Joseph Todisco is Chief Executive Officer of CorMedix Inc.. Currently has a direct ownership of 509,496 shares of CRMD, which is worth approximately $5.78 Million. The most recent transaction as insider was on Dec 18, 2025, when has been sold 30,000 shares (Common Stock) at a price of $12.0 per share, resulting in proceeds of $360,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 509K

0% 3M change

65.41% 12M change

Total Value Held $5.78 Million

Joseph Todisco Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 18 2025	SELL Open market or private sale	$360,000 $12.0 p/Share	30,000 Reduced 5.56%	509,496 Common Stock
Dec 18 2025	BUY Exercise of conversion of derivative security	$132,900 $4.43 p/Share	30,000 Added 5.27%	539,496 Common Stock
Sep 12 2025	SELL Open market or private sale	$650,000 $13.0 p/Share	50,000 Reduced 8.94%	509,496 Common Stock
Sep 12 2025	BUY Exercise of conversion of derivative security	$173,500 $3.47 p/Share	50,000 Added 8.2%	559,496 Common Stock
May 10 2025	SELL Payment of exercise price or tax liability	$247,483 $11.66 p/Share	21,225 Reduced 4.0%	509,496 Common Stock
Apr 01 2025	BUY Exercise of conversion of derivative security	$199,994 $3.38 p/Share	59,170 Added 10.03%	530,721 Common Stock
Jan 17 2025	SELL Payment of exercise price or tax liability	$291,800 $12.17 p/Share	23,977 Reduced 4.84%	471,551 Common Stock

Jan 17 2025	BUY Grant, award, or other acquisition	-	187,500 Added 27.45%	495,528 Common Stock
Jan 10 2025	SELL Payment of exercise price or tax liability	$199,506 $11.19 p/Share	17,829 Reduced 5.47%	308,028 Common Stock
May 10 2024	SELL Payment of exercise price or tax liability	$139,496 $5.17 p/Share	26,982 Reduced 7.65%	325,857 Common Stock
Mar 13 2024	BUY Open market or private purchase	$50,718 $3.74 p/Share	13,561 Added 3.7%	352,839 Common Stock
Jan 12 2024	SELL Payment of exercise price or tax liability	$47,820 $3.47 p/Share	13,781 Reduced 3.9%	339,278 Common Stock
Jan 12 2024	BUY Grant, award, or other acquisition	-	133,333 Added 27.41%	353,059 Common Stock
Sep 08 2023	BUY Open market or private purchase	$37,100 $3.71 p/Share	10,000 Added 4.35%	219,726 Common Stock
May 17 2023	BUY Grant, award, or other acquisition	$22,900 $4.58 p/Share	5,000 Added 2.33%	209,726 Common Stock
May 10 2023	SELL Payment of exercise price or tax liability	$198,447 $5.3 p/Share	37,443 Reduced 15.46%	204,726 Common Stock
Nov 15 2022	BUY Open market or private purchase	$76,400 $3.82 p/Share	20,000 Added 7.63%	242,169 Common Stock
Aug 24 2022	BUY Open market or private purchase	$18,424 $3.92 p/Share	4,700 Added 2.07%	222,169 Common Stock
May 16 2022	BUY Open market or private purchase	$33,800 $3.38 p/Share	10,000 Added 4.4%	217,469 Common Stock
May 10 2022	BUY Grant, award, or other acquisition	-	207,469 Added 50.0%	207,469 Common Stock

Also insider at

AMRX

Amneal Pharmaceuticals, Inc. Healthcare

Executive Vice President

ACRX

ACELRX PHARMACEUTICALS INC Healthcare

Joseph Todisco

Chief Executive Officer

Berkeley Heights, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRMD shares.

Notify only if

Value

Insider Trading

Get notified when an Cor Medix Inc. insider buys or sells CRMD shares.

Notify only if

Operation

Value

Type

News

Receive news related to CorMedix Inc.

Track Activities on CRMD

Account